PubMed Health⌕ Search

Biomedical subjects

L Lopez Bravo

Publications and source records attributed to L Lopez Bravo.

5 recordsLinked to original sources

Estimated number of leprosy cases in the world.

Planning for leprosy control requires estimates of the number of leprosy patients at different levels. During the period between the mid-1960s and the mid-1980s, global estimates had remained constant at between 10 and 12 million. The introduction of multidrug therapy (MDT) in many countries and the consequent reduction of the disease's prevalence has necessitated a reassessment of this. Based on available information and its interpretation, the number of leprosy cases in the world for 1991 has been estimated at 5.5 million. The number of individuals deformed by leprosy, including those cured of the disease, has been estimated at between 2 and 3 million.

Humans↗

Estimated number of leprosy cases in the world.

Planning for disease control requires estimates of the number of leprosy patients from local to global levels. From the mid-sixties to the mid-eighties, global estimates appeared to be constant at between 10 and 12 million. The introduction of multidrug therapy (MDT) in many countries and the consequent reduction of prevalence of the disease has necessitated a reassessment of the global estimate. Based on available information and its interpretation, the number of leprosy cases in the world in 1991 has been estimated at 5.5 million. The number of individuals with deformities due to leprosy, including persons now cured of the disease, has been estimated at between 2 and 3 million.

Epidemiologic Methods↗

Global review of multidrug therapy (MDT) in leprosy.

Leprosy continues to be an important public health problem in most countries of Asia, Africa and Latin America. While there has been a steady increase in the number of registered leprosy cases from 1966 to 1985, since then there has been a substantial reduction of over 30% in the number of registered cases. This is mainly attributed to the introduction of multidrug therapy (MDT) as recommended by a WHO study group on chemotherapy of leprosy for control programmes in 1981. The coverage for MDT has steadily increased over the last 5 years, reaching a global figure of 55.7% of all registered cases by October 1990. Over 2 million leprosy patients are currently undergoing MDT and, in addition, over 1 million patients have completed MDT since 1985. MDT has been found to be generally well tolerated with a high level of acceptability leading to improved treatment compliance. MDT coverage shows wide variations among WHO regions and among individual countries. The prospects for further reductions in prevalence of registered cases in the next decade are very bright. However, problems such as early case detection, and prevention and management of disabilities after patients have been curred for several years, will continue to pose significant challenges.

Africa↗

Estimated number of leprosy cases in the world.

Planning for disease control requires estimates of the number of leprosy patients from local to global levels. From the mid-sixties to the mid-eighties, global estimates appeared to be constant at between 10 and 12 million. The introduction of multidrug therapy (MDT) in many countries and the consequent reduction of prevalence of the disease has necessitated a reassessment of the global estimate. Based on available information and its interpretation, the number of leprosy cases in the world in 1991 has been estimated at 5.5 million. The number of individuals with deformities due to leprosy, including persons now cured of the disease, has been estimated at between two and three million.

Global Health↗